{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:42:11Z","timestamp":1793641331645,"version":"4.5.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507805"],"award-info":[{"award-number":["2023YFC2507805"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304600"],"award-info":[{"award-number":["2022YFC2304600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023020201010054"],"award-info":[{"award-number":["2023020201010054"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.thromres.2025.109527","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:01:26Z","timestamp":1762185686000},"page":"109527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed\/refractory B-ALL"],"prefix":"10.1016","volume":"256","author":[{"given":"Yingying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109527_bb0005","article-title":"The present and future for CAR-T cell therapy in adult B-cell ALL","author":"Roddie","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2025.109527_bb0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10299","key":"10.1016\/j.thromres.2025.109527_bb0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.thromres.2025.109527_bb0020","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Lu","year":"2020","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.thromres.2025.109527_bb0025","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/CM9.0000000000002288","article-title":"Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy","volume":"135","author":"Mei","year":"2022","journal-title":"Chin. Med. J."},{"issue":"3","key":"10.1016\/j.thromres.2025.109527_bb0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109527_bb0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.14680","article-title":"Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy","volume":"181","author":"Mei","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2025.109527_bb0040","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109527_bb0045","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.thromres.2025.109527_bb0050","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41409-021-01226-9","article-title":"CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I\/II clinical trial","volume":"56","author":"Shao","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.thromres.2025.109527_bb0055","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3324\/haematol.2022.281455","article-title":"Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy","volume":"108","author":"Song","year":"2023","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.thromres.2025.109527_bb0060","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.thromres.2025.109527_bb0065","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1007\/s00277-023-05477-y","article-title":"IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy","volume":"102","author":"Wang","year":"2023","journal-title":"Ann. Hematol."},{"issue":"17","key":"10.1016\/j.thromres.2025.109527_bb0070","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/bloodadvances.2020002060","article-title":"Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma","volume":"4","author":"Hashmi","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.thromres.2025.109527_bb0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18596","article-title":"Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells","volume":"201","author":"Galli","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2025.109527_bb0080","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109527_bb0085","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","article-title":"Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.thromres.2025.109527_bb0090","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy","author":"Da","year":"2024","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.thromres.2025.109527_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.thromres.2025.109527_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-a cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.thromres.2025.109527_bb0105","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.thromres.2025.109527_bb0110","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.thromres.2025.109527_bb0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-022-00777-4","article-title":"Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma","volume":"13","author":"Acosta-Medina","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.thromres.2025.109527_bb0120","article-title":"Timing of tocilizumab administration under the guidance of IL-6 in CAR-T therapy for R\/R acute lymphoblastic leukemia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109527_bb0125","first-page":"361","article-title":"Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation (version 2017)","volume":"38","author":"Thrombosis and Hemostasis Group HSoCMA","year":"2017","journal-title":"Chin. J. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109527_bb0130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.thromres.2025.109527_bb0135","first-page":"705","article-title":"Chinese guidelines for diagnosis and treatment of adult acute lymphoblastic leukemia (2021)","volume":"42","author":"Hematology Oncology Committee CA-CA, Leukemia, Lymphoma Group CSoHCMA","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.thromres.2025.109527_bb0140","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/hon.3155","article-title":"A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2","volume":"41","author":"Liu","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.thromres.2025.109527_bb0155","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1182\/bloodadvances.2022007454","article-title":"Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma","volume":"6","author":"Yamasaki-Morita","year":"2022","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.thromres.2025.109527_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"Moreno-Casta\u00f1o","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"21","key":"10.1016\/j.thromres.2025.109527_bb0200","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2025.109527_bb0210","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"43","key":"10.1016\/j.thromres.2025.109527_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.thromres.2025.109527_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.thromres.2025.109527_bb0225","doi-asserted-by":"crossref","first-page":"975","DOI":"10.21037\/atm-22-3814","article-title":"The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study","volume":"10","author":"Dong","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.thromres.2025.109527_bb0230","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.10454","article-title":"Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma","volume":"92","author":"Auwerda","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.thromres.2025.109527_bb0165","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.thromres.2025.109527_bb0170","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.thromres.2025.109527_bb0175","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.thromres.2025.109527_bb0180","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv."},{"issue":"22","key":"10.1016\/j.thromres.2025.109527_bb0185","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.thromres.2025.109527_bb0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01659-x","article-title":"Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed\/refractory acute lymphoblastic leukemia in children and young adults","volume":"18","author":"Breidenbach","year":"2025","journal-title":"J. Hematol. Oncol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:39:18Z","timestamp":1781019558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825002774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"alternative-id":["S0049384825002774"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109527","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed\/refractory B-ALL","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109527"}}